// App-Quantinova.ai

1106-47 : ABSENCE OF QTC PROLONGATION WITH BETRIXABAN: A RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND POSITIVE-CONTROLLED THOROUGH ECG STUDY

Researchers

Presenter

  • Uma Sinha

Principal Investigators

  • Joel Morganroth

  • Daniel D. Gretler

  • Stanley J. Hollenbach

  • Joseph L. Lambing

Medical Centers

  • N/A

Locations

  • N/A

Companies

  • Portola Pharmaceutic

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Venous thrombosis

Biomarkers

  • Apurinic/Apyrimidinic Endodeoxyribonuclease 1

  • Collagen type IV alpha 2 chain

Drug/Treatment

  • Moxifloxacin

  • betrixaban

  • Enoxaparin

  • Enoxaparin sodium

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved